Chemoimmunotherapy with low dose vinorelbine and interleukin-2 in treatment of patients with metastatic renal cell carcinoma

Neoplasma

Volumn 53, Issue 4, 2006, Pages 333-336

  Mencoboni, M P ^a   Tredici, S ^a   Varaldo, M ^a   Queirolo, G ^b   Durand, F ^b   Rebella, L ^c   Galbusera, V ^a   Pannacciulli, I M ^c   Ghio, R ^c  

^a VILLA SCASSI HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

Author keywords

Advanced renal carcinoma; Chemo immunotherapy

Indexed keywords

ALPHA INTERFERON; ANTIPYRETIC AGENT; INTERLEUKIN 2; NAVELBINE;

ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEMALE; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOTHERAPY; KIDNEY CARCINOMA; LUNG EDEMA; MALE; METASTASIS; NEPHROTOXICITY; NEUROTOXICITY; TREATMENT OUTCOME;

EID: 33746282197     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. PYRHONEN SO. Systemic therapy in metastatic renal cell carcinoma. Scand J Surg 2004; 93(2): 156-161.
2. MOTZER RJ, BACIK J, SCHWARTZ LH, REUTER V, RUSSO P et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004; 22(3): 454-463.
3. COPPIN C, PORZSOLT F, AWA A, KUMPF J, COLDMAN A et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005; (1): CD001425.
4. PORTA C, ZIMATORE M, IMARISIO I, NATALIZI A, SARTORE-BIANCHIA et al. Gemcitabine and oxaliplatin in the treatment of patients with immunotherapy-resistant advanced renal cell carcinoma: final results of a single-institution Phase II study. Cancer 2004; 100(10): 2132-2138.
5. FIZAZI K, ROLLAND F, CHEVREAU C, DROZ JP, MERY-MIGNARD D et al. A phase II study of irinotecan in patients with advanced renal cell carcinoma. Cancer 2003; 98(1): 61-65.
6. HAAS NB, GIANTONIO BJ, LITWIN S, MINNITI CJ JR, FOX S et al. Vinblastine and estramustine phosphate in metastatic renal cell carcinoma: a phase II trial of the Fox Chase Network. Cancer 2003; 98(9): 1837-1841.
7. BUKOWSKI RM. Renal cell carcinoma: treatment approaches for patients with advanced disease. Medical directions Publishings Co. Monteverde FLA, 1998.
8. HULAND E, HEINZER H. Renal cell carcinoma - innovative medical treatments. Curr Opin Urol 2004; 14(4): 239-244.
9. NEGRIER S, ESCUDIER B, LASSET C, DOUILLARD JY, SAVARY J et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. N Engl J Med 1998; 338(18): 1272-1278.
10. AULITZKY WE, KAUFMANN M. Immunotherapy for advanced renal cell carcinoma. Urologe A 2004; 43(1): 85-92.
11. BUKOWSKI RM. Role of Immunotherapy in Renal Cell Carcinoma. Medscape General Medicine 2000, 2(1).
12. ATZPODIEN J, KIRCHNER H, JONAS U, BERGMANN L, SCHOTT H et al. Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) Interleukin-2- and interferon alfa-2a-based immunochemotherapy in advanced renal cell carcinoma: a Prospectively Randomized Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN). J Clin Oncol 2004; 22(7): 1188-1194.
13. ATZPODIEN J, KUCHLER T, WANDERT T, REITZ M. Rapid deterioration in quality of life during interleukin-2- and alpha-interferon-based home therapy of renal cell carcinoma is associated with a good outcome. Br J Cancer 2003; 89(1): 50-54.
14. BUZIO C, ANDRULLI S, SANTI R, PAVONE L, PASSALACQUA R et al. Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma. Cancer 2001; 92(9): 2286-2296.
15. MORONI M, PORTA C, DE AMICI M, QUAGLINI S, CATTABIANI MA et al. Eosinophils and C4 predict clinical failure of combination immunotherapy with very low dose subcutaneous interleukin-2 and interferon in renal cell carcinoma patients. Haematologica 2000; 85(3): 298-303.
16. PAVONE L, ANDRULLI S, SANTI R, MAJORI M, BUZIO C. Long-term treatment with low doses of interleukin-2 and interferon-alpha: immunological effects in advanced renal cell cancer. Cancer Immunol Immunother 2001; 50(2): 82-86.
17. NEGRIER S, ESCUDIER B, DOVILLARD JY. Randomized study of interleukin 2 (IL-2) and interferon (INF) with or without 5-FU (FUCY study) in metastatic renal cell carcinoma (MRCC). Proc Am Soc Clin Oncol 1997; 16: 326a.
18. O'BRIEN MF, REA D, ROGERS E, BREDIN H, BUTLER M et al. Interleukin-2, interferon-alpha and 5-fluorouracil immunotherapy for metastatic renal cell carcinoma: the all Ireland experience. Eur Urol 2004; 45(5): 613-618.
19. PYRHONEN S, SALMINEN E, LEHTONEM T. Recombinant interferon alpha-2a with vinblastine vs vinblastine alone in advanced renal cell carcinoma. A phase III study. Proc Am Soc Clin Oncol 1996; 15: 244.
20. RATHMELL WK, MALKOWICZ SB, HOLROYDE C, LUGINBUHL W, VAUGHN DJ. Phase II trial of 5-fluorouracil and leucovorin in combination with interferon-alpha and interleukin-2 for advanced renal cell cancer. Am J Clin Oncol 2004; 27(2): 109-112.
21. PADRIK P, LEPPIK K, ARAK A. Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study. Urol Oncol 2004; 22(5): 387-392.
22. AMATO RJ. Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol 2005; 16(1): 7-15.
23. KONDAGUNTA GV, DRUCKER B, SCHWARTZ L, BACIK J, MARION S et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 2004; 22(18): 3720-3725.
24. MOTZER RJ, BACIK J, MAZUMDAR M. Prognostic factors for survival of patients with stage IV renal cell carcinoma. Clin Cancer Res 2004; 10: 6302-6303S.
25. MOTZER RJ, MADUMAZAR M, BACIK J, BERG W, AMSTERDAM A et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530.